All Access Articles |
- FDA Update – Insmed's Bronchiectasis Drug NDA Under Priority Review | 2025-02-24 | PHARMACEUTICAL
- Insmed Reports Strong Revenue Growth in 2024 | 2025-02-20 | PHARMACEUTICAL
- FDA Accepts Insmed's NDA for Brensocatib | 2025-02-06 | PHARMACEUTICAL
- INSM Craters Today, But Is Still Off 52 Week Low. | 2024-11-17 | PHARMACEUTICAL
- Insmed Ends 2023 with $780M Cash | 2024-02-22 | PHARMACEUTICAL